Clinical Trials Browser

Active not recruiting × Interventional × Patient Preference × Clear all

NCT06101134 2026-04-09

A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations

Phase 2 Active not recruiting

100 enrolled 11 charts

Melanoma, Neoplasm Metastasis, Patient Preference

NCT05883956 2025-03-20

PREFER-HMA

Phase 3 Active not recruiting

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Patient Preference